The Triage BNP test is a rapid immunoassay blood test that aids in the diagnosis of congestive heart failure, assessment of disease severity, and risk stratification of patients with acute coronary syndromes. Biosite Inc recently announced that the US Food and Drug Administration (FDA) cleared a new indication for its Triage BNP test. This test can also now be used to help physicians assess the risk of mortality or rehospitalization in heart-failure patients. It is a portable, quantitative, rapid diagnostic test that can be used at the point of care or in a central laboratory. By providing critical diagnostic information to the physician, the Triage BNP test may improve detection of congestive heart failure, leading to earlier therapeutic intervention, which could prevent advancement of the disease. Biosite also recently announced that the FDA has granted a CLIA waiver for the test, substantially expanding health care professionals’ access to the 15-minute blood test.
Biosite Inc
(800) 745-8026; www.biosite.com
